Eli Lilly Stock: 1 Red Light, 1 Green Light
Shares of Eli Lilly lagged the broader market in 2013 by a wide margin. While some investors may see this as an opportunity to jump into a sector filled with sky-high valuations, it's important to first weigh both the pros and cons of this particular stock. In the following video, analyst Max Macaluso focuses on one headwind, namely the affect of the "patent cliff" on Lilly's top and bottom lines, and one tailwind, the drugs Lilly is developing, that will have huge impacts on the stock this year.
The Motley Fool's Top Stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The article Eli Lilly Stock: 1 Red Light, 1 Green Light originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.